Literature DB >> 29089593

New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Masayuki Igarashi1, Yoshimasa Ishizaki1, Yoshiaki Takahashi1.   

Abstract

Tuberculosis is one of the most common and challenging infectious diseases worldwide. Especially, the lack of effective chemotherapeutic drugs for tuberculosis/human immunodeficiency virus co-infection and prevalence of multidrug-resistant and extensively drug-resistant tuberculosis remain to be serious clinical problems. Development of new drugs is a potential solution to fight tuberculosis. In this decade, the development status of new antituberculous drugs has been greatly advanced by the leading role of international organizations such as the Global Alliance for Tuberculosis Drug Development, Stop Tuberculosis Partnership and Global Health Innovative Technology Fund. In this review, we introduce the development status of new drugs for tuberculosis, focusing on those derived from natural products.The Journal of Antibiotics advance online publication, 1 November 2017; doi:10.1038/ja.2017.126.

Entities:  

Year:  2017        PMID： 29089593     DOI： 10.1038/ja.2017.126

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  142 in total

1.  Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Authors:  Kenneth N Olivier; David E Griffith; Gina Eagle; John P McGinnis; Liza Micioni; Keith Liu; Charles L Daley; Kevin L Winthrop; Stephen Ruoss; Doreen J Addrizzo-Harris; Patrick A Flume; Daniel Dorgan; Matthias Salathe; Barbara A Brown-Elliott; Renu Gupta; Richard J Wallace
Journal:  Am J Respir Crit Care Med       Date:  2017-03-15       Impact factor: 21.405

2.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Authors:  Barbara A Brown-Elliott; Julie V Philley; David E Griffith; Foram Thakkar; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.

Authors:  Marina Protopopova; Colleen Hanrahan; Boris Nikonenko; Rowena Samala; Ping Chen; Jackie Gearhart; Leo Einck; Carol A Nacy
Journal:  J Antimicrob Chemother       Date:  2005-09-19       Impact factor: 5.790

4.  Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Koen Andries; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Rifampicin: a new orally active rifamycin.

Authors:  N Maggi; C R Pasqualucci; R Ballotta; P Sensi
Journal:  Chemotherapy       Date:  1966       Impact factor: 2.544

6.  Acyldepsipeptide antibiotics induce the formation of a structured axial channel in ClpP: A model for the ClpX/ClpA-bound state of ClpP.

Authors:  Dominic Him Shun Li; Yu Seon Chung; Melanie Gloyd; Ebenezer Joseph; Rodolfo Ghirlando; Gerard D Wright; Yi-Qiang Cheng; Michael R Maurizi; Alba Guarné; Joaquin Ortega
Journal:  Chem Biol       Date:  2010-09-24

7.  SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.

Authors:  Kapil Tahlan; Regina Wilson; David B Kastrinsky; Kriti Arora; Vinod Nair; Elizabeth Fischer; S Whitney Barnes; John R Walker; David Alland; Clifton E Barry; Helena I Boshoff
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

8.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.

Authors:  Won-Jung Koh; Seung Heon Lee; Young Ae Kang; Chang-Hoon Lee; Jae Chol Choi; Jae Ho Lee; Seung Hun Jang; Kwang Ha Yoo; Ki Hwan Jung; Ki Uk Kim; Sang Bong Choi; Yon Ju Ryu; Kyung Chan Kim; Soojung Um; Yong Soo Kwon; Yee Hyung Kim; Won-Il Choi; Kyeongman Jeon; Yong Il Hwang; Se Joong Kim; Young Seok Lee; Eun Young Heo; Juhee Lee; Yeo Woon Ki; Tae Sun Shim; Jae-Joon Yim
Journal:  Am J Respir Crit Care Med       Date:  2013-10-01       Impact factor: 21.405

10.  Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection.

Authors:  Sasha J Rose; Mary E Neville; Renu Gupta; Luiz E Bermudez
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240
View more
  8 in total

Review 1.  Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.

Authors:  Estefania Grotz; Nancy Tateosian; Nicolas Amiano; Maximiliano Cagel; Ezequiel Bernabeu; Diego A Chiappetta; Marcela A Moretton
Journal:  Pharm Res       Date:  2018-09-20       Impact factor: 4.200

Review 2.  Plant-Derived Natural Products as Lead Agents against Common Respiratory Diseases.

Authors:  Ayodeji Oluwabunmi Oriola; Adebola Omowunmi Oyedeji
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

3.  Naphthoquinone Derivatives as Scaffold to Develop New Drugs for Tuberculosis Treatment.

Authors:  Priscila C B Halicki; Laís A Ferreira; Kelly C G De Moura; Paula F Carneiro; Karina P Del Rio; Tatiane Dos S C Carvalho; Maria do C F R Pinto; Pedro E A da Silva; Daniela F Ramos
Journal:  Front Microbiol       Date:  2018-04-09       Impact factor: 5.640

4.  Identification of Substituted Amino Acid Hydrazides as Novel Anti-Tubercular Agents, Using a Scaffold Hopping Approach.

Authors:  Alistair K Brown; Ahmed K B Aljohani; Fatimah M A Alsalem; Joseph L Broadhead; Jason H Gill; Yucheng Lu; Jonathan D Sellars
Journal:  Molecules       Date:  2020-05-21       Impact factor: 4.411

Review 5.  Recent Developments on the Synthesis and Bioactivity of Ilamycins/Rufomycins and Cyclomarins, Marine Cyclopeptides That Demonstrate Anti-Malaria and Anti-Tuberculosis Activity.

Authors:  Uli Kazmaier; Lukas Junk
Journal:  Mar Drugs       Date:  2021-08-03       Impact factor: 5.118

6.  Screening of Microbial Fermentation Products for Anti-M. tuberculosis Activity.

Authors:  Aikebaier Reheman; Di Lu; Yifan Wang; Xi Chen; Gang Cao; Chuanxing Wan
Journal:  Animals (Basel)       Date:  2022-07-31       Impact factor: 3.231

7.  Glabridin Plays Dual Action to Augment the Efficacy and Attenuate the Hepatotoxicity of Methotrexate in Arthritic Rats.

Authors:  Ashish Dogra; Dilpreet Kour; Mahir Bhardwaj; Sumit Dhiman; Amit Kumar; Bhavna Vij; Ajay Kumar; Utpal Nandi
Journal:  ACS Omega       Date:  2022-09-14

8.  Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates.

Authors:  Wei Zhou; Bing Yang; Yanyan Zou; Khaista Rahman; Xiaojian Cao; Yingying Lei; Ren Lai; Zhen F Fu; Xi Chen; Gang Cao
Journal:  Front Microbiol       Date:  2021-06-30       Impact factor: 5.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.